Serum Institute of India on Saturday said that it is all set to launch Covovax, a vaccine against coronavirus that has been developed in partnership with Novavax, by June this year. The company CEO Adar Poonwalla on Saturday said his company is looking forward to new venture and aims to develop approximately 1 billion of vaccine candidate for low and middle income countries.
The announcement follows Thursday’s development wherein the company had said that its vaccine was 89.3 per cent effective against new coronavirus variant that was discovered in the UK, according to a preliminary analysis.
Poonawalla took to Twitter to inform about SII’s partnership with Novavax for a coronavirus vaccine has given excellent efficacy results. “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch COVOVAX by June 2021!” he tweeted.
After the result, Serum Institute CEO Adar Poonawalla on Thursday told reuters that the company has now sought approval to conduct vaccine trials in India.
“We have already applied to the drug controller’s office for the bridging trial, a few days ago… So they should also give that approval soon now,” the news agency quoted him as saying. He added that by April, the company would be producing 40-50 million doses of the vaccine candidate per month.
India is currently conducting its inoculation programme with Serum Institute’s Covishield and Bharat Biotech’s Covaxin. Under the pan-India vaccination drive, as many as 29 lakh people, including healthcare and frontline workers, have been administered the vaccine so far.